Search

You searched for "lesions"

2370 results found
Ophthalmic Epidemiology cover picture

Impact of WASH factors on trachoma prevalence

4 December 2024 | | EYE - Cornea
Trachoma is the leading infectious cause of blindness globally. Following a national population-based trachoma survey in Malawi, one round of azithromycin mass drug elimination (MDA) was carried out successfully – that is, the prevalence of trachomatous inflammation, follicular (TF) in...
Ophthalmic Epidemiology cover picture

Epidemiology of ocular cancer in Cali

4 December 2024 | | EYE - Pathology, EYE - Oncology
The aim of this study was to describe the population trends of incidence and survival rates of ocular cancer in Cali, Columbia. Data was retrieved from the Registro Poblacion de Cancer de Cali (RPCC, i.e. Population Cancer Registry of Cali)...
Ophthalmic Genetics cover picture

Reproductive counselling for females with X-linked inherited retinal diseases

2 October 2025 | | EYE - Vitreo-Retinal
The authors report a survey-based study of 118 female patients who were genetically confirmed carriers or obligate carriers of an X-linked inherited retinal disease. The majority (66.9%) of these patients were carriers of choroideremia; other diagnoses included retinitis pigmentosa, X-linked...

In conversation with Robert F Walters

24 September 2019
We chatted to Robert F Walters, Orbis Trustee at ESCRS 2019. In the series of videos below he gives us a brief overview of the work Orbis is doing globally, the challenges faced in treating refugees including avoidable blindness and...

Haag-Streit UK to move away from NHS Supply Chain

28 May 2025 | Contracts & Distributors, Company Profiles
Haag-Streit UK has announced that they will no longer be working with NHS Supply Chain. To provide a more flexible, transparent procurement process, Haag-Streit UK will be supplying their products direct to NHS trusts and ophthalmic healthcare providers from 1st...

Evolving towards an interventional glaucoma mindset

2 February 2024 | | EYE - Glaucoma
Traditionally, a newly diagnosed glaucoma patient would be treated first with medical therapy. As the disease progressed or the initial intervention failed to adequately control intraocular pressure (IOP), clinicians would add more drops, selective laser trabeculoplasty (SLT), repeated SLT and...

Improving eye care for children with learning difficulties: a view from SeeAbility

1 August 2019 | | EYE - General
Marek P Karas from sightloss charity SeeAbility examines why children with a learning disability do not access the eye care they need and asks how the system needs to change. Children with a learning disability are 28 times more likely...

What's trending Jun/Jul 2022

1 June 2022 | | EYE - General
A round-up of the eye-related hot topics that have been trending over the last few weeks. #Polishdoctor #UkraineConflict #familysight Polish doctor Professor Rejdak’s team saved a Ukrainian family’s eyesight after a bomb hit their home. Olena Selichzianowa and her 5-year-old...

Optometry Today’s new education resource for practice teams

9 August 2023 | OT, AOP, Optometry Today, Optometry, Johnson & Johnson, Education, Training
Optometry Today (OT) has released a new education package for optometry practice teams, delivered in partnership with the Association of Optometrists (AOP) and Johnson & Johnson Vision.

CHEC expands transformative MIGS service

23 September 2024 | industry, private sector, glaucoma, MIGS, surgery, healthcare, Minimally invasive
CHEC, a community healthcare provider delivering specialist ophthalmology services on behalf of the NHS, has announced the expansion of its minimally invasive glaucoma surgery (MIGS) service. MIGS is an innovative approach combining glaucoma treatment with cataract surgery, utilising advanced techniques...

First treatment for late-stage dry AMD rejected by UK drug regulator

17 February 2025 | AMD, geographic atrophy, Dry, macular society, Apellis, pharma
Leading sight loss charity the Macular Society has responded to the decision not to approve the first potential treatment for geographic atrophy (GA) or late stage dry aged-related macular degeneration. The decision is a significant setback for those affected by...